Keywords
How to Cite
Abstract
There are considered medications used to treat melanoma starting with dacarbazine and ending with immunotherapeutic drugs accepted for practical applying in recent years. For each medication its effectiveness in different parameters, main targets and mechanisms of action are characterized.References
Дементьева Н.П., Корман Д.Б. Нитрозометилмочевина - 30 лет изучения и применения для лечения онкологических больных // Вопр.онкол. - 2001. - № 6. - С. 55-661.
Корман Д.Б., Микаэлян С.Г, Пинес Е.В., Снимщиков В.А. Влияние химиотерапии на выживаемость больных с диссеминированной меланомой кожи // Сов. медицина. - 1987. - № 10. - С.102-105.
Корман Д.Б. Мишени и механизмы действия противоопухолевых препаратов. - М.: Практическая медицина, 2014. - 333 с.
Эммануэль Н.М., Корман Д.Б., Островская Л.А. и др. Нитрозоалкилмочевины - новый класс противоопухолевых препаратов. - М.:Наука, 1978. - 295 с.
Agarwala S.S., Kirkwood J.M., Glore M. et al. Temozolo-mide for the treatment of brain metastases associated with metastatic melanoma: a phase II study // J. Clin. Oncol. - 2004. - Vol. 22. - P. 2101-2107.
Avrie M.F., Aamadal S., Grob J.J. et al. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study // J. Clin. Oncol. -2004. - Vol. 22. - P. 1118-1125.
Carbe C., Eigantler T.K., Keilholz U. et al. Systematic review of medical treatment in melanoma: current status and future prospects // Oncologist. - 2011. - Vol. 16. - P. 5-24.
Carvajal R.D., Sosman J.A., Queredo J.F. et al. Effect of selumetinibe versus chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial // JAMA. - 2014. - Vol. 311. - P. 2397-2405.
ComachoL.H., Antonia S., Sosman J.et al. Phase I/II trial of tremelimumab in patients with metastatic melanoma // J. Clin. Oncol. - 2009. - Vol. 27. - P. 1075-1081.
Duan L., Mukherjel E.M., Narayen D. Tailoring the treatment of melanoma: implications for personalized medicine // Yal. J. Biol. Med. - 2015. - Vol. 88. - P. 389-395.
Dummer R., Goldinger S.M., Tutschi C. et al. Vemurafenib in patients with BRAF (V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study // Eur. J. Cancer. - 2014. - Vol. 50. - P. 611-621.
Eggermont A.M., Kirkwood J.M. Re-eveluating the role of dacarbazine in metastatic melanoma: whay have we learned in 30 years // Eur. J. Cancer. - 2004. - Vol. 40.- P. 1825-1836.
Eggermont A.M, Chiarion-Sileni V., Garob J.J. et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomized double-blinde, phase III trial // Lancet Oncol.- 2015. - Vol. 16. - P. 522-530.
Eigentler T.K., Gutzmer R., Hauschild Y et al. Adjuvant treatment with pegylated interferon-alfa-2a versus low-dose interferon-alfa-2a in patients with high-risk melanoma: a randomized phase III De C06 trial // Ann. Oncol. - 2016. - Vol. 27. - P. 1625-1632.
Falchook G., Lewis K.D., Infante J.R. et al. Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase I dose-escalation trail // Lancet Oncol. - 2012. - Vol. 13. - P. 782-789.
Flaherty K.T., Infante J.R., Daud et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations // N. Engl. J. Med. - 2012. - Vol. 367. - P. 16941703.
Flaherty L., Hami O., Linette G. et al. A single-arm, open-label, expanded eccess study of vemurafenib in patients with metastatic melanoma in the United States // Cancer. - 2014. - Vol. 20. - P. 18-24.
Greg S.L. Talmogene laherparepvec: first global approval // Drugs. - 2016. - Vol. 76. - P. 147-154.
Hauschild A., Grob J.J., Dewidov L.V. et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicenter, open-label, phase III, randomized controlled trial // Lancet. - 2102. - Vol. 380. - P. 358-365.
Hersh E.M., O'Day S.J., Powdeily J. et al. A phase II multicenter study of ipilimumab with and without dacarbazine in chemotherapy-naive patients with advanced melanoma // Invest.New Drugs. - 2011. - Vol. 29. - P. 489-498.
Ives N.J., Stow R.L., Lovigan P., Wheatly K. Chemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: a meta-analysis of 12 trials involving 2621 patients // J. Clin. Oncol. - 2007. - Vol. 25. - P. 5426-5436.
Jiang G., Li.R.H., Sun C. et al. Efficacy ana safety between temozolamide alone and telozolamide-based double therapy for malignant melanoma: a meta-analysis // Tumour Biol. - 2014. - Vol. 35. - P. 315-322.
Johnson D.B., Puzanov I., Velley M.C. Talmogne laherparepvec (T-VEC) for the treatment of advanced melanoma // Immenother. - 2015. - Vol. 7. - P. 611-619.
Kaufman H.L., Amatruda T., Reid T. et al. Systemic versus local response in melanoma patients terated with talmogene laherpareprec from a multi-instititional phase II study // J. Immunother Cancer. - 2016. - Vol. 4. - P. 12. - 10 1186/s4042-016-0116-2 DOI: 10.1186/s4042-016-0116-2
Khan N., Gucalp R., Shapira I. Evolving concepts: immunity in oncology from targets to treatment // J. Clin. Oncol. - 2015. - Article d.847363. - apr28. - DOI: 10.1155/2015/847383
Kirkwood J.M., Bastholt L., Robert C. et al. Phase II open-label, randomized trial of the MEK1/2 inhibitor selumetinib in patients with advanced melanoma // Clin. Cancer Res. - 2012. - Vol. 18. - P. 555-567.
Larkin J., DelVeccio M., Ascierto P.A. et al. Vemurafenib in patients with BRAF (V600) mutated metastatic melanoma: open-label, multicenter, safety study // Lancet Oncol. -2014. - Vol. 15. - P. 436-444.
Larkin J., Ascierto P.A., Dreno B. et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma // N. Engl. J. Med. - 2014. - Vol. 371. - P. 1867-1876.
Luke J.J., Hodi F.S. Ipilimumab, vemurafenib, dabrafenib and trametinib: synergistic competations in the clinical management of BRAF mutant malignant melanoma // Oncologist. - 2013. - Vol. 18. - P. 717-725.
Liong G.V., Stroykovskiy D., Goga S. et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma // N. Engl. J. Med. - 2014. - Vol. 371. - P. 1877-1888.
Maio M., Grob J.J., Aamdal S. et al. Five-year survival rates for treatment-nave patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial // J.Clin.Oncol. - 2015. - Vol. 33. - P. 1191-1196.
Malas S., Harrasser M., Lacy K.E., Karagionnis S.H. Antibody therapyies for melanoma: new and emerging opportunities to activate immunity (review) // Oncol. Rep. - 2014. - Vol. 32. - P. 875-886.
Mangana J., Cheng P.F., Schidler K.et al. Analysis of BRAF and NRAS mutation status in advanced melanoma patients treated with anti-CTLA-4 antibodies: association with overall survival // PLoS One. - 2015. - Vol. 10 (10). - el 0139438.
McArthur G.A., Chapman P.B., Robert C. et al. Safety and efficacy of vemurafenib in BRAF V600E and BRAF V600K mutation-positive melanoma (BRIM-3); extended follow-up of phase3, randomized open-label study // Lancet Oncol. - 2014. - Vol. 15. - P. 323-332.
Menzies A.M., Long G., Murali R. Dabrafenib and its potential for the treatment of metastatic melanoma // Drug Des. Devel. Ther. - 2012. - Vol. 6. - P. 391-405.
Menzies A.M., Long G.V. Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma // Clin.Cancer Res. - 2014. - Vol. 20. - P. 2035-2043.
Metcalfe W., Anderson J., Trinth V., Hwu W.J. Antiprogrammed cell death-1 (PD1) monoclomal antibodies in treating advanced melanoma // Discov. Med. - 2015. - Vol. 106. - P. 393-401.
Michelin O., Holler C. Gaining momentum: new options and opportunities for the treatment of advanced melanoma // Cancer Treat. Rev. - 2015. - Vol. 41. - P. 660-670.
Middleton M.R., Giol J.J., Aaronson N. et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic melanoma // J. Clin. Oncol. - 2008. - Vol. 18. - P. 158-166.
Mocellin S., Pasquali S., Rossi C.R., Nitti D. Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematric review and meta-analysis // J. Natl. Cancer Inst. - 2010. - Vol. 102. - P. 493-501.
Ott P.A., Hodi F.S., Robert C. CTLA-4 and PD1/PDL1 blackage: new immuno-therapeutic modalities with durable clinical benefit in melanoma patients // Clin. Cancer Res. - 2013. - Vol. 19. - 5300.
Patel S.P., Woodman S.E. Profile of ipilimumab and its role in the treatment of metastatic melanoma // Drug Des. Devel. Ther. - 2011. - Vol. 5. - P. 489-495.
Petrolla T, Quirt I., Verma S. et al. Single-agent interleukin-2 in the treatment of metastatic melanjoma // Curr. Oncol. - 2007. - Vol. 14. - P. 21-26.
Prietro P.A., Yang J.C., Sherry R.M. et al. CTLA-4 blockage with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma // Clin. Cancer Res. - 2012. - Vol. 18. - P. 2039-2047.
Ribas A., Kefford R., Marshall H.A. et al. Phase III randomized clinical trial comparing tremelimumab with standart of care chemotherapy in patients with advanced melanoma // J. Clin. Oncol. - 2013. - Vol. 31. - P. 616622.
Ribas A., Puzanov I., Dummer R. et al. Pembrolizumab versus investigator choice chemotherapy for ipilimumab-refractory melanoma ( KEYNOTR-002): a randomized, controlled, phase 2 trial // Lancet Oncol. - 2015. - Vol. 18. - P. 908-918.
Ribas A., Hamid O., Daud A. et al. Association of pembrolizumab with tumor response and survival among patients with advanced melanoma // JAMA. - 2016. - Vol. 135. - P. 1600-1609.
Robert C., Dummer R., Gutzmer R. et al. Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomized study // Lancet Oncol. - 2013. - Vol. 14. - P. 733-740.
Robert C., Schadendorf D., Messina M. et al. Efficacy and safety of retreatment with ipilimumab in patients with pretreated advanced melanoma who progressed after initially achieving disease control // Clin. Cancer Res. - 2013. - Vol. 19. - P. 2232-2230.
Robert C., Ribas A., Wolckok J.D. et al. Anti-programmed -death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomized dose-comparison cohort of a phase I trial // Lancet. - 2014. - Vol. 384. - P. 1109-1117.
Robert C., Karaszewska B., Schacter J. et al. Improved overall survival in melanoma with combined dabrafenib and trametinib // N. Engl. J. Med. - 2015. - Vol. 372. - P. 30-39.
Robert C., Schacter J., Long G.V. et al. Pemobrolizumab versus ipilimumab in advanced melanoma // N. Engl. J. Med. - 2015. - Vol. 372. - P. 2521-253.
Schadendorf D., Hodi F.S., Robert C. et al. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unrectable or metastatic melanoma // J. Clin. Oncol. - 2015. - Vol. 33. - P. 1889-1894.
Scott L.L. Nivolumab: a review in advanced melanoma // Drugs - 2015. - Vol. 12. - P. 1413-1424.
Serrone L., Zeuli H., Sega F.M., Cognett F. Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview // J. Exp. Clin. Cancer - 2000. - Vol. 19. - P. 21-34.
Sullivan R.J., Flaherty K. Resistance to BRAF-targed therapy in melanoma // Eur. J. Cancer. - 2013. - Vol. 99. - P. 1294-1304.
Topalian S.L., Sznol M., McDermott D.F. et al. Survaival, durable tumor remission and long-term safety in patients with advanced melanoma receiving nivolumab // J.Clin. Oncol. - 2014. - Vol. 32. - P. 1020-1030.
Tran K.H., Cheng M.Y, Mitra A. et al. MEK inhibitors and their potential in the treatment of advanced melanoma: the advantages of combination therapy // Drug Devel. Ther. - 2016. - Vol. 10. -P. 43-52.
Vallet H., Caillet A., Weiss N. et al. Pembrolizumab-induced necrotic myositis in a patient with metastatic melanoma // Ann. Oncol. - 2016. - mdw126. DOI: 10.1093/annonc/
Vockens C.J., Goldinger S.M., Loquai C. et al. The price of tumor control: an analysis of a rare side effects of an-ti-CTLA-4 therapy in a metastatic melanoma from the ipilimumab network // PLoS One. - 2013. - Vol. 8. - e53745.
Wolchok J. How recent advances in immunotherapy are changing the standart of care for patients with metastatic melanoma // Ann. Oncol. - 2012. - Vol. 33. - Suppl.8. - P. 15-21.
Wolchok J.D., Hodi F.S., Weber J.S. et al. Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma // Ann. N.Y Acad. Sci. - 2013. - Vol. 129. - P. 1-13.
Wolchok J.D., Weber J.S., Maio M. et al. Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials // Ann. Oncol. - 2013. - Vol. 24. - P. 2174-2180.
Yang H.S., Chapman P.B. The history and future of chemotherapy for melanoma // Hematol. Oncol. Clin. North Am. - 2009. - Vol. 23. - P. 583-590.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
© АННМО «Вопросы онкологии», Copyright (c) 2017